The Stanley Brothers has given large participants in its Birchal crowdfunding raise the chance to purchase additional shares at the current offer price of 35 cents per share for a period of up to two years.
Describing the arrangement as an Australian first in equity crowdfunding, the company said the deal is open to investors committing more than A$50k in the raise, which closed on Thursday.
The company also noted that the warrant comes with no upfront costs and carries no obligation for investors to follow through on additional share purchases.
As of 8.40am on Thursday, Stanley Brothers had raised $746k from 439 investors as part of its broader plan to build an "army of advocates" to push for regulatory reform in Australia.
The company's prospectus shows it is seeking to raise up to a maximum of $3m.
Separately, through its joint venture with FoliuMed, Stanley Brothers said it is "actively pursuing" deals in the US, Brazil, Colombia, Germany, and other European Union countries following its Australian market entry.
The company added: "Unlike typical international cannabis brands that operate locally or within a single market, Stanley Brothers is set to become the first globally recognised brand in medical cannabis. This ambition sets a new benchmark in the industry. Australia is paramount to this."
FoliuMed, which carries out manufacturing and R&D in Germany and cultivation in South America, announced last year that it had partnered with the Stanley Brothers to enter the Australian market.
The two companies are working together to initially bring three medicines to market through the Special Access Scheme, with a wider product range planned for the future.
